1.

Fig 1 -

2.

Fig 1 -

3.

Fig 1 -

4.

Fig 1 -

5.

Fig 1 -

6.

Fig 1 -

7.

Fig 1 -

8.

Fig 1 -

9.

Fig 1 -

1.

Sankey diagram of the origin and genetic context of mcr -genes.

2.

Sankey diagram of the origin and genetic context of mcr -genes.

3.

Sankey diagram of the origin and genetic context of mcr -genes.

4.

Sankey diagram of the origin and genetic context of mcr -genes.

5.

Sankey diagram of the origin and genetic context of mcr -genes.

6.

Sankey diagram of the origin and genetic context of mcr -genes.

7.

Sankey diagram of the origin and genetic context of mcr -genes.

8.

Sankey diagram of the origin and genetic context of mcr -genes.

9.

Sankey diagram of the origin and genetic context of mcr -genes.

1.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

2.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

3.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

4.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

5.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

6.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

7.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

8.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

9.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

1.

Fig 4 -

2.

Fig 4 -

3.

Fig 4 -

4.

Fig 4 -

5.

Fig 4 -

6.

Fig 4 -

7.

Fig 4 -

8.

Fig 4 -

9.

Fig 4 -

1.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

2.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

3.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

4.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

5.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

6.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

7.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

8.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

9.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

1.

Comparison of colistin resistance between Belgium and the Netherlands by measurement and by sector.

2.

Comparison of colistin resistance between Belgium and the Netherlands by measurement and by sector.

3.

Comparison of colistin resistance between Belgium and the Netherlands by measurement and by sector.

4.

Comparison of colistin resistance between Belgium and the Netherlands by measurement and by sector.

5.

Comparison of colistin resistance between Belgium and the Netherlands by measurement and by sector.

6.

Comparison of colistin resistance between Belgium and the Netherlands by measurement and by sector.

7.

Comparison of colistin resistance between Belgium and the Netherlands by measurement and by sector.

8.

Comparison of colistin resistance between Belgium and the Netherlands by measurement and by sector.

9.

Comparison of colistin resistance between Belgium and the Netherlands by measurement and by sector.

1.

Association of colistin resistance with prior colistin use in pig farms in Belgium (n = 14) and the Netherlands (n = 15).

2.

Association of colistin resistance with prior colistin use in pig farms in Belgium (n = 14) and the Netherlands (n = 15).

3.

Association of colistin resistance with prior colistin use in pig farms in Belgium (n = 14) and the Netherlands (n = 15).

4.

Association of colistin resistance with prior colistin use in pig farms in Belgium (n = 14) and the Netherlands (n = 15).

5.

Association of colistin resistance with prior colistin use in pig farms in Belgium (n = 14) and the Netherlands (n = 15).

6.

Association of colistin resistance with prior colistin use in pig farms in Belgium (n = 14) and the Netherlands (n = 15).

7.

Association of colistin resistance with prior colistin use in pig farms in Belgium (n = 14) and the Netherlands (n = 15).

8.

Association of colistin resistance with prior colistin use in pig farms in Belgium (n = 14) and the Netherlands (n = 15).

9.

Association of colistin resistance with prior colistin use in pig farms in Belgium (n = 14) and the Netherlands (n = 15).

1.

Partners of the ESCAPE-NET consortium.

2.

Partners of the ESCAPE-NET consortium.

1.

Decision tree.

2.

Decision tree.

1.

Average total healthcare costs per patient in both groups.

2.

Average total healthcare costs per patient in both groups.